Drug Metabolism in Drug Design and Development Basic Concepts and Practice

Bufurarol

BDS Hypersil

C8, 5

m

m,

2

50 mm

0–50% B

1.9 min linear

(^01)
-OH-Bufurarol278.1/186.1
DL
-Propranolol260.2/155.1
CYP2E1
Chlorzoxazone
Synergy Polar-RP
4
m
m, 50
4.6 mm
20–80% B
2 min linear
6-OH-Chlorzoxazone
168.1/132.0
Cpd A 202.2/155.1
CYP3A4
Nifedipine
BDS Hypersil
C8, 5
m
m,
2
50 mm
0–50% B
1.9 min linear
Oxidized nifedipine
344.9/284.1
Nimodipine
419.1/343.2
CYP3A4
Testosterone
BDS Hypersil
C8, 5
m
m,
2
50 mm
0–50% B
1.9 min linear
6 b
-OH-Testosterone305.5/269
Cortisone
361.0/163.2
Dextromethorphan
XDB C8, 5
m
m,
2.1
50 mm
Agilent
0–60% B
2.1 min linear
3-Methoxymorphinan
258.2/171.1
Levallorphan
284.1/199.2
Diazepam
Extend-C18,
3.5
m
m,
4.6
50 mm
30–70% B
7.0 min linear
Temazepam
270.9/140.0
Lorazepam
320.9/275.2
Nordiazepam
Extend-C18,
3.5
m
m,
4.6
50 mm
30–70% B
7.0 min linear
Oxazepam
292.0/246.2
Lorazepam
320.9/275.2
Midazolam
ACE 5 C18-A3654
5
m
m, 4.6
50 mm
10–80% B
2.5 min linear
(^01)
-OH-Midazolam342.1/203.1
Triazolam
343.1/308.1
519